Safety evaluation of irinotecan delivery to a rat glioma model using a clinical MRI-guided system

Project Name: Safety evaluation of irinotecan delivery to a rat glioma model using a clinical MRI-guided system
Status: Complete
Primary Site: Brigham and Women's Hospital
Funded Date: Jun 04, 2018
Funding Program: Research Award
Funding Period: Jun 04, 2018 - Aug 04, 2019
Amount Awarded: $49,334.89
Category: Brain tumors, Glioblastoma

Abstract

This work will test the hypothesis FUS-induced blood-brain barrier disruption can be used to deliver irinotecan to the brain and to a brain tumor model without toxicity. We will use the 230 kHz ExAblate Neuro clinical transcranial MRI-guided FUS system for these tests. First, in healthy rats we will deliver free and liposomal irinotecan across the BBB and use histology to confirm that such delivery is not neurotoxic. Next, we will evaluate this chemotherapy agent in a rat glioma model. At 3-4 weeks after sonication, we will examine the brains in histology to assess tumor volume, side effects, and infiltration in comparison to animals that did not receive focused ultrasound-induced BBB disruption.

Contact Roles

Reports

No reports found.

The Focused Ultrasound Foundation Newsletter

Our newsletter delivers updates for clinicians, researchers and patients. Sign up and stay on top of the rapid advancements of this innovative medical technology.

Sign Up  Read the Latest Issue

Read The Tumor  by John Grisham

From John Grisham, comes a story where today’s medical fiction could become tomorrow’s lifesaving reality.

Download a Free eBook or Audiobook

Contact Details

Call Us
434.220.4993
Find Us
Focused Ultrasound Foundation
1230 Cedars Court, Suite 206 Charlottesville, VA 22903
Email